Comparison of the effectiveness of dornase alfa in chronic rhinosinusitis with nasal polyposis using different types of drug delivery

Abstract

Introduction. When using the drug dornase alfa in children with cystic fibrosis (CF) in the form of inhalations through a compressor inhaler with a pulsating aerosol supply, a high concentration of aerosol is achieved in the nasal cavity and paranasal sinuses, which reduces the severity of rhinological pathology, namely chronic rhinosinusitis, including those with nasal polyposis. There is also a positive effect on the function of external respiration, due to a decrease in the negative impact of rhinological pathology on the respiratory tract, primarily due to descending infection.Aim. To evaluate the effect of intranasal dornase alfa therapy as part of a complex treatment on lung function and indicators of physical development in children with CF.Materials and methods. The study compared the effectiveness of the drug dornase alfa for chronic rhinosinusitis with nasal polyposis using different types of drug delivery in children who did not receive targeted therapy for CF. A group of children who received two inhalations of dornase alfa (n = 43), information about patients in this group was taken from the 2020 register, and a group of children who received inhalation of dornase alfa only in the lower respiratory tract were compared (n = 28), information about patients in this group was taken from the 2016 register.Results. The effect of additional intranasal inhalation of the drug dornase alfa was observed in the form of an increase in FEV and FVC. In addition, there was an improvement in body weight and height in the group of patients receiving intranasal inhalations, but the identified difference did not reach significant values.Conclusion. The results obtained in the form of an increase in FEV1 and FVC allow us to draw a conclusion about the effectiveness of prescribing additional intranasal inhalation of the drug dornase alfa.